CKD-519

Catalog No. :
ACKFII126
CAS No. :
1402796-27-3
Molecular Formula :
C31H34F7NO3
Molecular Weight :
601.60

IUPAC Name:(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one

CKD-519 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg99%$203.00Login to see priceInquiryInquiry
5mg99%$526.00Login to see priceInquiryInquiry
10mg99%$841.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameCKD-519
IUPAC Name(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one
Molecular FormulaC31H34F7NO3
Molecular Weight601.60
SMILESO=C1O[C@H](C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)[C@H](C)N1CC3=C(C4=CC(C(C)C)=C(F)C=C4OC)CCC(C)(C)C3
InChI KeyGBHPDJQHZADVAA-SOKVYYICSA-N
SynonymCKD-519 | DB15437 | Rocacetrapib [INN] | GBHPDJQHZADVAA-SOKVYYICSA-N | CS-0063731 | UNII-K9SP3L3YQP | 2-Oxazolidinone, 5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylethyl)phenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-4-methyl-,
CAS No.1402796-27-3
PubChem CID70674853

Synthetic Route by SureRoute

1. ACKFII126 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACOKCX098 route compound structure diagram
    ACOKCX098875446-29-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKFII126 route product structure diagram
    ACKFII1261402796-27-3
Inquiry

2. ACKFII126 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKFII126 route product structure diagram
    ACKFII1261402796-27-3
Inquiry

Comments (0)